Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M

Amylyx Pharmaceuticals, Inc.

2023-FY EPS reported $0.70 revenue$380,786,000

Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.
Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.
Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.
Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.
Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amylyx Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $108.4 million, net income $4.7 million.

Period: the fourth quarter ended December 31, 2023
Revenue: $108.4 million
Net income: $4.7 million
Result: reported results

Exact text from the filing

• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amylyx Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $380.8 million, net income $49.3 million.

Period: the fiscal year ended December 31, 2023
Revenue: $380.8 million
Net income: $49.3 million
Result: reported results

Exact text from the filing

• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.